Planned use of GP IIb/IIIa inhibitors is safe and effective during implantation of the Absorb Bioresorbable Vascular Scaffold
| Autor: | Susan Marks, Alex Kirby, David B. Jessup, Matthew Grove |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
Platelet Membrane Glycoprotein IIb Target lesion medicine.medical_specialty Abciximab Coronary Artery Disease 030204 cardiovascular system & hematology Coronary Angiography 03 medical and health sciences Percutaneous Coronary Intervention 0302 clinical medicine Chart review Absorbable Implants medicine Humans Bare metal 030212 general & internal medicine Stent thrombosis Infusions Intravenous Retrospective Studies Bioresorbable vascular scaffold Aged 80 and over Dose-Response Relationship Drug Tissue Scaffolds business.industry Drug-Eluting Stents General Medicine medicine.disease Thrombosis Surgery Treatment Outcome surgical procedures operative Tirofiban Conventional PCI Female Cardiology and Cardiovascular Medicine business Platelet Aggregation Inhibitors Mace Follow-Up Studies |
| Zdroj: | Cardiovascular Revascularization Medicine. 19:956-959 |
| ISSN: | 1553-8389 |
| Popis: | Bioresorbable Vascular Scaffolds (BVS) have the potential for adaptive vessel remodeling, restoration of vasomotion, and late luminal enlargement, thus allowing them to circumvent target lesion failures associated with bare metal stents (BMS) and drug-eluting stents (DES). However, recent data has shown a concerning increase in BVS-associated scaffold thrombosis (ScT) compared to DES. Upfront administration of GP IIb/IIIa inhibitors (GPIs) has shown to reduce early stent thrombosis (ST) compared to standard of care in BMS and DES. Since the use of GPIs was limited in BVS studies, the effect of GPIs on the rate of BVS-associated ScT is largely unknown. This is the first study investigating whether a planned use of GPIs during implantation of the Absorb BVS represents a safe and effective strategy in reducing ScT. In a retrospective chart review of 22 patients undergoing PCI with BVS implantation and planned GPI administration, no acute ScT, in-hospital MACE, or in-hospital major/minor bleeding events were observed. Bleeding reduction strategies such as shorter GPI infusion and radial access were implemented. This study provides valuable preliminary evidence on the benefit and safety in using planned GPI administration to reduce the incidence of ScT after implantation of BVS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect